SEC Filing Summary: Pieris Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Pieris Pharmaceuticals, Inc. on March 22, 2017. The filing serves to announce financial results for the fiscal year ended December 31, 2016, via an attached press release (Exhibit 99.1). The registrant is a Nevada corporation headquartered in Boston, MA.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing text does not provide data to compare current period results against prior comparable periods. No specific material changes in financial condition or operations are detailed in the provided excerpt.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information under Item 2.02 and the attached exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other filings unless expressly stated. The text does not contain specific management commentary, forward-looking guidance, risk factors, or details on contingencies and unusual items.
Investor Verification Checklist
- Verify the specific financial results (revenue, net loss, cash position) by reviewing the attached press release (Exhibit 99.1) referenced in this filing.
- Confirm the company's cash runway and burn rate based on the full 2016 financial statements.
- Review the full press release for any updates on clinical trial progress or regulatory milestones not detailed in this summary.
- Note that the financial data in this 8-K is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.